|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Other current assets | ||||||||||||||||||||
| Marketable securities, current | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Marketable securities, long-term | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Operating lease right-of-use assets | ||||||||||||||||||||
| Other non-current assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accrued compensation and employee benefits | ||||||||||||||||||||
| Accrued expenses and other liabilities | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Total accrued expenses and other liabilities | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued expenses and other current liabilities | ||||||||||||||||||||
| Operating lease liability, current | ||||||||||||||||||||
| Related party common stock warrant liability | ||||||||||||||||||||
| Related party accounts payable and other current liabilities | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Operating lease liability, non-current | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Convertible preferred stock, value | ||||||||||||||||||||
| Stockholders’ equity: | ||||||||||||||||||||
| Series B non-voting convertible preferred stock, $0.001 par value; 251,504 shares authorized as of June 30, 2026 and December 31, 2025; 137,138 shares issued and outstanding as of June 30, 2026 and December 31, 2025 | ||||||||||||||||||||
| Series A Non-Voting Convertible Preferred Stock | ||||||||||||||||||||
| Series B Non-Voting Convertible Preferred Stock | ||||||||||||||||||||
| Series B Non-Voting Convertible Preferred Stock | ||||||||||||||||||||
| Common stock, $0.001 par value; 545,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 61,069,887 and 48,722,309 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive income (loss) | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||||||
| Total liabilities and stockholders’ equity |
Loading...
